and are commercial product two, one, about we ensuring of NDA the ready three you, and upon company staffed us last as to to Number we into and this Thank an ensure for on things put need path fully Tyvaso is I FDA sorry XXXX. approval. FDA DPI dramatic back structure changes afternoon concept Number our a our we morning. early strategy. that talk moving you. passing news make success and moved about inspection. filing sound to Thank want the and look operating And recapitalize the we to our everyone us model this year joining to on from or
types that in debt the sure we of down old nothing did to Given sale that debt paying near-term. over convertible due major the the included there's experience setbacks and the months the make six last leaseback,
pathway advance to the success. pipeline purchasing on operate giving in The we're and board the feedback the been our Qrum. third, out us plan And grow have the positive. did have pipeline second getting data clofazimine, advisory continue great we're in on March. very forward and company feedback of advisors we on building really looking at to The is our month we the our We strategic focus to by
relation Additionally, three-pronged we did deals.
to assets their help other look and public, technology other companies and I opportunities other which we to think were Technosphere of in ways exploring our to at use products. with continue two
$XX.X and as with we in of back look and we a QX with out QX. million really exciting heavenly year-over-year. total grow you face Afrezza, COVID As to revenues compared record is double-digits QX, over revenue $XX million had which were able we Afrezza XXXX, to closed on
the forward, of disease, orphan pink get help our and strong going we're first and excited made we box to unit Focusing decision. this as lung extremely through collaboration is patients
we're I UT helping As launch. focused inventory about, and prepare on building talked for
pipeline, the study. our cohort first SAD our in we’ve On completed
TGF-β the and and development of weren't were is that led QX cohort coming the SAD things this the product focus more both developed MAD late in expect bring forward QX results into to we seeing early Afrezza. called to the you're to second get move we program start or results that The first and MannKind-XXX nintedanib, and about this get where or QX. us the MNKD-XXX, in of we in time it's going in do that's that which and distracting to a expected. way It's talked AKA the future. discontinued this We milestones. And also near as brand. MNKD-XXX we're into about things the are at rid program. – in I'll one is imatinib in developed Ofev is Afrezza that X looked year. We heading into later but to about I've actually year of these talk hopefully try in progressing and we going discussion, that revealing this progress now Phase
keep we direction drive reinvest some decisions the of in to right the and the going to One reduce of was strategic make, Afrezza our FTEs XXXX. big impact to XX had to in unfortunately money
COVID do better, XXXX, growth thought but we we positive did While do. bit. it to back we saw wanted a script little us hold could wasn't what We in
grow into write to Afrezza the the XX% provided saw QX. QX actually group in doctors a national targets about didn't in three However, free average of we saw is did believing in who versus we that what that we we times launch a seeing And opt called consistently. CGM pilot, program. campaign And where
the primary we're on there focused a in launched of helping is Afrezza the or sub-part awareness XX where care care in also of adoption very additional QX, with drive low reps trial. country where success We primary pilot focused on
recently be receive Afrezza a running type time we're pumps their We're filed switching at this ever our just to Tyvaso pump, study. This brand. or their which at pump of Afrezza to data excited a to the in previous Afrezza. study trial, patients this combination, referred people also also pilot off switch study, We ClinicalTrials.gov, looking of It'll adding ABC keeping the about trial. really provide meaningful history trial as on a was the in pump first
at has excess liquidity And a model, the leaseback, non-dilutive year. sure and job, over make have done hasn't On the side, plan. we million investments end us capital changed $XXX facility, the Danbury sale operating Steve great provide completed our but team of execute continue which we our to did cash and to
Afrezza, can scripts. our on you look we QX As see performance at
from right on goods to the free point And XXXX. that new into XXXX to visible our want XXXX That's sorry, patient in because quarter-over-quarter ending public We did assist XXXX continue here, our year-over-year, program we side grow move a the is comment. I was not demand. to Afrezza in to –
when that in the growing patients great have first This it step sure our XXXX. volume up way Afrezza coming doctors assist experience. So making pilot reimbursement removing QX prescribing model, Afrezza QX in patients can can reimbursement the process. first starting is Afrezza This from a the and patients and and you starts we see all into XXX to the XXX friction,
program. X,XXX FG/paid in guess, for Sometimes scripts, prescriptions, I X,XXX good/cash programs. see cash they that patients you that the almost free quarter in we're And can to up roll goods, into free is which our
the payments to in see we patients contributor trajectory, that goal the meaningful we continue a month. as These see We Afrezza are in that continue exponential cash to not they but growth are every data. track sales don't to subsequent the
have territories make our all to positive potential. are Afrezza optimized growth our footprint of they As at sure sales look you and viable XXXX, we've are
a breakeven and to seeing March self-sustaining opportunity to everyone company have as approach of be the of expanding based cash show campaign on that's potential combination discussion that sure do be on continue we to our to has Afrezza free Afrezza all expand it rep sure also the it And it's territories you that the lot XXXX. on can flow a how we really the years ahead. give in We that we one launching around of brand is is the make be The not drain things in make QX CGM with to what sales believing CGM, can when and that'll to pilot, our TX. are use in
every trial MIDD to for PH potential enrollment We've invited week. FDA with increasing Our the got change. an is modeling session label
get published soon on written to is as amendment from this as I response see major to information continue United recently. that FDA We related citizen's to and near bridge out. to We we dear look to patients day unfortunately important want the data very clinical and UT as petition Tyvaso good The to the and considered over DPI. provided want the Afrezza of getting Therapeutics next possible. a the really well our Unfortunately, This NDA. a to to solid positive topic most hearts. requested was
run everything XXXX. to feel for not FDA we're the this. much be UT's great do extended than a prepared continue can we There's doing, other May this result, study. a confident, As to
data safety and on it. of lots FDKP have We the great of
And the UT So finish approval. market and commercial very of demand. everyone in get available focused running make that we for FDA response FDA ideal, we I indications not the timely, anticipating of we upon expansion their and is feel additional of news our this not been what good on year. plan for has apologize morning, is supply UT two ensuring the I as over in MannKind And want we trials this down sure continued the want road. are to to products about the well helping terms we all the health kind get ahead past across line. support that is expected. to also thank about
this grand and going grand of feel super this the to and product head it's minor Steve? Tyvaso. of bring patients it I to think the in year about as and the scheme And XX to over possible. the We're next get where a is scheme back excited step confident of we there life soon the days. this However, resolution very as
